NCT05551767

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Induction Immunochemotherapy in Stage III-IVa Cancer of Oropharynx, Hypopharynx and Larynx

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: City Clinical Oncology Hospital No 1 · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS\>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.

Detailed description

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS\>1 will recieve 3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation. Effect of induction therapy will be assesed by PET/CT and by endoscopic evaluation with biopsy of suspected residual tumor. Managemant of any residual tumor will be performed according with local rules and standards.

Conditions

• Neck Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)

Timeline

• Start date: 2022-08-30
• Primary completion: 2023-12-30
• Completion: 2024-12-30
• First posted: 2022-09-23
• Last updated: 2022-09-23

Locations

3 sites across 1 country: Russia